The negative correlation between ITGAV expression and tumor purity further suggests that elevated ITGAV levels may foster a more immune-enriched microenvironment, potentially improving patient prognosis and increasing the efficacy of immunotherapy, especially in COAD and PRAD. Here, ITGAV is linked to prostate adenocarcinoma.